You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 21, 2024

PF PRISM CV Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for PF PRISM CV
International Patents:613
US Patents:29
Tradenames:11
Ingredients:11
NDAs:16

Drugs and US Patents for PF PRISM CV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv XALKORI crizotinib CAPSULE, PELLETS;ORAL 217581-003 Sep 7, 2023 RX Yes Yes 7,858,643 ⤷  Sign Up Y Y ⤷  Sign Up
Pf Prism Cv BOSULIF bosutinib monohydrate TABLET;ORAL 203341-002 Sep 4, 2012 RX Yes No 7,767,678*PED ⤷  Sign Up Y ⤷  Sign Up
Pf Prism Cv XELJANZ tofacitinib citrate TABLET;ORAL 203214-002 May 30, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up
Pf Prism Cv XALKORI crizotinib CAPSULE, PELLETS;ORAL 217581-002 Sep 7, 2023 RX Yes No 7,825,137 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PF PRISM CV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv XELJANZ tofacitinib citrate TABLET;ORAL 203214-002 May 30, 2018 7,842,699 ⤷  Sign Up
Pf Prism Cv ZMAX azithromycin FOR SUSPENSION, EXTENDED RELEASE;ORAL 050797-001 Jun 10, 2005 7,887,844 ⤷  Sign Up
Pf Prism Cv TORISEL temsirolimus SOLUTION;INTRAVENOUS 022088-001 May 30, 2007 RE44768*PED ⤷  Sign Up
Pf Prism Cv RAPAMUNE sirolimus TABLET;ORAL 021110-001 Aug 25, 2000 5,100,899*PED ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for PF PRISM CV drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 1 mg and 5 mg ➤ Subscribe 2018-02-23
➤ Subscribe Tablets 400 mg ➤ Subscribe 2018-10-15
➤ Subscribe Tablets 50 mg and 200 mg ➤ Subscribe 2008-04-14
➤ Subscribe For Injection 50 mg per vial ➤ Subscribe 2009-06-15
➤ Subscribe Tablets 1 mg and 2 mg ➤ Subscribe 2009-12-17
➤ Subscribe Extended-release Tablets 50 mg and 100 mg ➤ Subscribe 2012-02-29
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-05-10
➤ Subscribe Tablets 5 mg ➤ Subscribe 2016-11-07
➤ Subscribe Tablets 100mg and 500mg ➤ Subscribe 2016-09-06
➤ Subscribe For Injection 200 mg/vial ➤ Subscribe 2008-09-12
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2010-10-08
➤ Subscribe Injection 25 mg/mL, 1.8 mL vial ➤ Subscribe 2011-05-25
➤ Subscribe Tablets 0.5 mg ➤ Subscribe 2010-08-25
➤ Subscribe Extended-release Tablets 25 mg ➤ Subscribe 2015-05-08

Supplementary Protection Certificates for PF PRISM CV Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0536515 C300244 Netherlands ⤷  Sign Up PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424
1218348 2013/008 Ireland ⤷  Sign Up PRODUCT NAME: AXITINIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/777/001 EU/1/12/777/006 20120903
0401747 25/2001 Austria ⤷  Sign Up PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: LI 5524301 20000926
0440372 02C0030 France ⤷  Sign Up PRODUCT NAME: VORICONAZOLE; NAT. REGISTRATION NO/DATE: EU/1/02/212/001-025 20020319; FIRST REGISTRATION: EU/1/02/212/001-25 20020319
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.